NewsPublic figure
Michael Bolton's Brain Cancer: Understanding Glioblastoma
Singer Michael Bolton shared his glioblastoma diagnosis. Here's a plain-language look at brain tumors and how they are treated, from NCI resources.
A plain-language summary based on public reporting and trusted sources, linked below.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
What Michael Bolton has said
Michael Bolton is a Grammy-winning singer. In April 2025 he told People that he has glioblastoma. TODAY and NBC News reported it.
Bolton said he learned of the diagnosis in December 2023. It came after emergency surgery to remove a brain tumor. He had a second brain surgery in January 2024 to treat an infection. He finished radiation and chemotherapy in October 2024. He said he now has an MRI scan every two months.
He also said treatment has affected his short-term memory, his mobility, and his speech. In December 2025 his daughters told AARP that he was in good spirits and good health.
That is the whole of what has been shared. Nothing here predicts what comes next for him. The rest of this page is about the medicine.
Glioblastoma in plain terms
The brain is held together by glial cells. They feed and protect nerve cells. One kind of glial cell is the astrocyte, named for its star shape. A tumor that starts in astrocytes is an astrocytoma.
The National Cancer Institute grades these tumors from I to IV. Grade IV is glioblastoma. NCI describes it as a tumor that grows and spreads very quickly. Its cells look very different from normal cells under a microscope.
Anaplastic astrocytomas and glioblastomas together make up about 38 percent of primary brain tumors, NCI reports. Primary means the tumor started in the brain. That is not the same as cancer that spread to the brain from the lung or the breast. Our page on brain tumors sets out the main types.
NCI notes that primary brain tumors rarely spread to other parts of the body. They spread within the brain and spine instead. That is one reason surgery alone seldom clears them.
How the diagnosis is made
Symptoms usually come first, because a tumor takes up space inside a closed skull and presses on nearby tissue.
NCI lists the tests used. A neurological exam checks mental status, coordination, walking, muscles, senses, and reflexes.
Imaging comes next. An MRI uses a magnet, radio waves, and a computer to build detailed pictures. A dye called gadolinium is put into a vein. It gathers around tumor cells and makes them brighter.
Imaging can suggest a tumor. It cannot name it. A biopsy does that. A surgeon takes a sample of tissue, and a pathologist studies the cells. Sometimes the sample comes out during the operation to remove the tumor. NCI notes that a biopsy is not always possible.
The lab also looks for molecular markers. NCI names three that carry weight in glioma: methylation of the MGMT gene promoter, changes in the IDH1 or IDH2 genes, and loss of parts of chromosomes 1p and 19q. Methylation means a chemical tag that quiets a gene. These findings help shape care.
The standard course of treatment
NCI states the standard for newly diagnosed glioblastoma plainly. Surgery comes first. Then radiation and daily temozolomide together. Then six cycles of temozolomide alone.
Temozolomide is a chemotherapy taken by mouth. NCI lists it as approved for glioblastoma with radiation, then alone as maintenance.
Surgeons take out as much tumor as they safely can. The limit is function. NCI notes that grade IV tumors usually cannot be removed completely.
The trial behind this plan enrolled 573 people. Radiation alone was compared with radiation plus temozolomide. Radiation was 60 Gy, given in 2 Gy doses over six weeks. Survival was better in the combined group, with a hazard ratio for death of 0.6. Survival at three years was 16.0 percent with the combination and 4.4 percent with radiation alone.
A later look at the same trial tested the MGMT marker. Median overall survival was 18.2 months when the MGMT promoter was methylated and 12.2 months when it was not. NCI also reports that adding bevacizumab to radiation and temozolomide did not improve overall survival. Our page on radiation therapy covers what those weeks involve.
Signs worth a doctor's attention
NCI says the signs are not the same in every person. They depend on where the tumor is, what that part of the brain controls, and how large it is. Other conditions cause them too. Check with a doctor about:
- A morning headache, or a headache that goes away after vomiting
- Seizures
- Trouble with vision, hearing, or speech
- Frequent nausea and vomiting
- Loss of appetite
- Changes in personality, mood, focus, or behavior
- Loss of balance, or trouble walking
- Weakness
- Unusual sleepiness, or a change in activity level
A first seizure in an adult needs urgent assessment. So does a headache that is new, severe, and unlike any before it.
What the numbers describe
SEER tracks brain and other nervous system cancer across the United States. Those figures cover every type in that group, not glioblastoma alone. Glioblastoma sits at the harder end of the range.
The American Cancer Society expects 24,740 new cases and 18,350 deaths in 2026, and NCI's SEER program hosts that forecast. SEER's own measurement is the survival figure: 32.9 percent at five years for cases from 2016 to 2022.
These are group averages. They come from thousands of people of different ages, with different tumors, treated in different years. They do not describe any one reader. Our page on understanding cancer survival statistics explains why.
What this does not mean
NCI states that it does not have evidence-based information about preventing brain tumors, and none about screening for them either. There is no recommended test for people without symptoms. NCI also says the cause of most adult brain and spinal cord tumors is not known. A public diagnosis does not change any of that.
It also does not mean headaches are usually tumors. They usually are not.
One person's course tells you nothing about another's. Tumor grade, molecular markers, age, health, and how much tumor a surgeon can safely remove all pull in different directions. A median is the middle of a wide spread, with people on both sides of it.
Sources
- NCI PDQ, Adult Central Nervous System Tumors Treatment (Health Professional Version) — https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq
- NCI PDQ, Adult Central Nervous System Tumors Treatment (Patient Version) — https://www.cancer.gov/types/brain/patient/adult-brain-treatment-pdq
- NCI, Brain and Spinal Cord Tumors — https://www.cancer.gov/types/brain
- NCI, Temozolomide — https://www.cancer.gov/about-cancer/treatment/drugs/temozolomide
- SEER Cancer Stat Facts, Brain and Other Nervous System Cancer — https://seer.cancer.gov/statfacts/html/brain.html
- TODAY, Michael Bolton reveals glioblastoma diagnosis — https://www.today.com/health/disease/michael-bolton-reveals-glioblastoma-diagnosis-rcna203703
- TODAY, Michael Bolton's daughters reveal how he is doing now — https://www.today.com/health/men-s-health/michael-bolton-brain-cancer-daughters-update-rcna250484
- NBC News, Michael Bolton reveals glioblastoma diagnosis — https://www.nbcnews.com/pop-culture/pop-culture-news/michael-bolton-reveals-glioblastoma-diagnosis-find-re-made-rcna203765
How this article was prepared
An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.
The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.
See an error, old source, or unclear wording? Tell us.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Brain tumor (glioblastoma). The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.